11:11am Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal MT
11:10am Partners Group Holds $650 Million First Close for Fifth Real Estate Secondaries Program MT
08:49am Richemont Kept at Hold as Berenberg Notes 'Unquestionable' Asset Quality; Price Target Rises MT
06:33am Novartis Reports Positive Biomarker Data for Del-Brax in Muscular Dystrophy Study MT
06:19am Roche's Tecentriq, Chemotherapy Combo Gets US FDA Priority Review for Colon Cancer MT
06:00am Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint DJ
06-10 Sadif Downgrades Swisscom to Strong Sell, Trims PT MT
06-10 Sadif Investment Analytics Downgrades Partners Group to Sell MT
06-10 Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon RE
06-10 Logitech Launches Foldable Mouse MT
06-10 Holcim Unveils Carbon Capture Test Platform in France MT
06-10 AlphaValue/Baader Europe Cuts EPS Forecasts for Lonza Group on Division Sale MT
06-10 Australia's REA Group falls after UBS downgrade on volume risks from tax changes RE
06-09 UBS, Givaudan Drive Swiss Shares Higher as Middle East Tensions Ease MT
06-09 Deutsche Bank Upgrades Givaudan to Buy, Raises PT MT
06-09 Rothschild & Co. Redburn Cuts Partners Group PT, Maintains at Neutral MT
06-09 Swiss Lawmakers Consider Easing Proposed Capital Rules for UBS MT
06-09 Lonza Group: Incorporating Capsules & Health Ingredients divestment Alphavalue
06-09 Swiss Lawmakers Consider Easing Proposed Capital Rules for UBS MT
06-09 Partners Group Mulls EUR200 Million Joint Investment in Debt-laden Emeria MT
06-09 Switzerland Reportedly Considering Softening Capital Requirements for UBS MT
06-09 Swiss Lawmakers Consider Easing Proposed Capital Rules for UBS MT
06-09 Roche sticks to German investment after Eli Lilly cuts RE
06-09 Sika Commissions New Automated Concrete Admixtures Site in Belgium MT
06-09 SIKA OPENS STATE-OF-THE-ART PRODUCTION AND CONCRETE SERVICE HUB IN THE BENELUX REGION DJ
No results match your criteria
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!